Search - tctmd.com

Displaying 1 - 20 of 64

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Conference News TCT 2023

Comparing DCBs in De Novo CAD: Drugs, Design Matter

Caitlin E. Cox

October 25, 2023

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Daily News

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

L.A. McKeown

August 16, 2021

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

News Conference News EuroPCR 2019

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

L.A. McKeown

May 22, 2019

News Conference News SCAI 2019

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Yael L. Maxwell

May 21, 2019

News Daily News

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

Todd Neale

January 15, 2019

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Daily News

Use of DAPT Score Following PCI Validated in PRODIGY Study

Yael L. Maxwell

June 12, 2017

News Industry News

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

May 25, 2017

Presentation

10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents

February 13, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Los Balones Recubiertos de Fármacos son Más Aptos para el Manejo de la Reestenosis Intra-Stent en SMD que en SLF

Caitlin E. Cox

August 17, 2016

News Daily News

Drug-Coated Balloons Best Suited for In-Stent Restenosis in BMS, not DES

Caitlin E. Cox

August 17, 2016

News Daily News

CABG Shows Survival Advantage Over PCI in Nondiabetic Patients With Multivessel Disease

L.A. McKeown

June 29, 2016

News Daily News

A Tight Spot: Drug-Eluting Stents Seem to Top Other Options for Small-Vessel Disease

Todd Neale

June 16, 2016

News Daily News

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Michael O'Riordan

June 06, 2016

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

What’s Going to Be Hot at TCT 2025

Comparing DCBs in De Novo CAD: Drugs, Design Matter

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

DCB in Diabetes Show Promising Long-term Outcomes: BASKET-SMALL 2

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

BASKET-SMALL 2 Angiographic Substudy Supports Safety of DCBs in Small Coronary Vessels

Paclitaxel DCBs and CHIP: SCAI Kicks Off With Two Hot-Potato Topics

Slight Advantage for DES Over DCB for In-Stent Restenosis: Updated Meta-analysis

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Use of DAPT Score Following PCI Validated in PRODIGY Study

STENTYS: Follow-Up of the APPOSITION IV and OPEN II Clinical Trials at Respectively 3 and 4 Years Confirms the Initial Positive Study Outcomes

10-Year Clinical Outcome After Randomization to Sirolimus- or Paclitaxel-Eluting Coronary stents

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Los Balones Recubiertos de Fármacos son Más Aptos para el Manejo de la Reestenosis Intra-Stent en SMD que en SLF

Drug-Coated Balloons Best Suited for In-Stent Restenosis in BMS, not DES

CABG Shows Survival Advantage Over PCI in Nondiabetic Patients With Multivessel Disease

A Tight Spot: Drug-Eluting Stents Seem to Top Other Options for Small-Vessel Disease

Higher Scaffold Thrombosis Risk With Absorb BVS vs a Wide Range of Stents: Network Meta-Analysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content